IP/IV Chemotherapy Associated With Improved Survival in Ovarian Cancer

Share this content:
Intraperitoneal and intravenous (IP/IV) chemotherapy was associated with significantly improved overall survival in patients with ovarian cancer.
Intraperitoneal and intravenous (IP/IV) chemotherapy was associated with significantly improved overall survival in patients with ovarian cancer.

Intraperitoneal and intravenous (IP/IV) chemotherapy was associated with significantly improved overall survival in patients with ovarian cancer, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

Previous research demonstrated that IP/IV chemotherapy administered to patients with ovarian cancer resulted in a 16-month survival benefit.

Therefore, researchers sought to assess the use and effectiveness of IP/IV chemotherapy in women with ovarian cancer in clinical practice.

Researchers identified 823 women with stage 3, optimally cytoreduced ovarian cancer who were diagnosed at six National Comprehensive Cancer Network institutions between 2003 and 2012 and compared them with 402 controls diagnosed between 2006 and 2012.

Results showed that IP/IV chemotherapy was linked with significantly improved 3-year overall survival compared with IV chemotherapy (HR = 0.68; 95% CI: 0.47, 0.99).

IP/IV chemotherapy was also associated with more frequent changes to chemotherapy delivery route versus IV chemotherapy (OR = 2.83; 95% CI: 1.47, 5.47).

RELATED: Younger Women May Face Worse Ovarian Cancer Outcomes After Primary Therapy

Researchers found that IP/IV chemotherapy use increased from 0% in 2003 to 50% in 2008, but only 4% to 67% of institutions adopted IP/IV chemotherapy between 2006 and 2012 (P<0.001).

Moreover, 43% of patients received modified IP/IV chemotherapy regimens at the time of treatment initiation.

The findings suggest that increasing IP/IV chemotherapy use in clinical practice may be an underused but important strategy to improve outcomes in patients with ovarian cancer.

Reference

  1. Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2015.61.4776.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs